Introduction
RANKL, a member of the TNF superfamily of cytokines, is an obligate factor required for osteoclast differentiation and survival, lymph node organogenesis, lymphocyte development, and breast epithelial proliferation (1) (2) (3) (4) (5) (6) . Mice deficient in RANKL develop severe osteopetrosis due to low bone turnover as a result of absent functional osteoclasts (3) . Inhibition of RANKL is now a major therapeutic modality in treating diseases of high bone turnover states, such as osteoporosis.
RANKL signals principally through the 2 transcription factors nuclear factor of activated T cells c1 (NFATc1) and NF-κB (2, 3, 7, 8) . In addition to the induction of the osteoclastogenic master transcription factor NFATc1 by RANKL signaling, osteoclast development requires modulation of 2 additional signaling pathways: the coordinated activation of the SRC tyrosine kinase (9, 10) with the simultaneous inhibition of the Wnt/β-catenin pathway (11) (12) (13) .
We previously reported that the adaptor protein 3BP2, which is encoded by the SH3BP2 locus, is essential for normal osteoclast formation, since Sh3bp2 -/-mice show reduced bone resorption due to a cell-autonomous osteoclast defect (14) . We have shown that 3BP2 nucleates a signaling complex, including SRC, VAV, and SYK, and that SRC activation is impaired in 3BP2-null osteoclasts. Constitutively active SRC rescues defective osteoclastogenesis observed in Sh3bp2 -/-macrophages, demonstrating that SRC activation by 3BP2 is essential for normal osteoclast development.
3BP2 ligates the SRC SH3 domain, enforcing an open active configuration of SRC, and is both sufficient and necessary for SRC kinase activation in osteoclasts (14) .
3PB2 is subject to tight negative regulation by tankyrase, a poly(ADP-ribose) polymerase (PARP) family member. Tankyrase-mediated 3BP2 ribosylation creates a recognition site for the E3 ubiquitin ligase RNF146, leading to its proteasomal degradation (15) . Gain-of-function missense mutations in the SH3BP2 gene, which are associated with cherubism, a rare genetic syndrome characterized by bone dysplasia and remodeling of the facial bones (15) (16) (17) , uncouple 3BP2 from tankyrase/RNF146, stabilize 3BP2 protein, and cause hyperactivation of SRC, SYK, and VAV. A genetically engineered mouse model of cherubism harboring one of the cherubism mutations develops hyperactive osteoclasts and a lethal systemic inflammatory disorder characterized by monocytic infiltration of visceral organs and elevated levels of TNF-α (18) . Osteoclasts derived from the cherubism mice have increased endogenous 3BP2 protein levels and highly active SRC (15) . 3BP2 is thus a concentration-limited adapter protein that controls SRC, VAV, and SYK activity in the monocyte lineage (15) , yet little is currently known about how 3BP2 protein levels are controlled during osteoclastogenesis.
The Wnt/β-catenin pathway antagonizes normal osteoclastogenesis. β-Catenin-deficient (Ctnnb1 -/-) mice display osteoporosis due to enhanced osteoclast differentiation, whereas mice harboring a constitutively active form of β-catenin are osteopetrotic due to defective osteoclastogenesis (11) (12) (13) . β-Catenin is negatively regulated by a destruction complex that includes AXIN (19) , glycogen synthase kinase-3β (GSK-3β), adenomatous polyposis coli (APC), and the E3 ubiquitin ligase β-TrCP and leads to its phosBone undergoes continuous remodeling due to balanced bone formation and resorption mediated by osteoblasts and osteoclasts, respectively. Osteoclasts arise from the macrophage lineage, and their differentiation is dependent on RANKL, a member of the TNF family of cytokines. Here, we have provided evidence that RANKL controls the expression of 3BP2, an adapter protein that is required for activation of SRC tyrosine kinase and simultaneously coordinates the attenuation of β-catenin, both of which are required to execute the osteoclast developmental program. We found that RANKL represses the transcription of the E3 ubiquitin ligase RNF146 through an NF-κB-related inhibitory element in the RNF146 promoter. RANKL-mediated suppression of RNF146 results in the stabilization of its substrates, 3BP2 and AXIN1, which consequently triggers the activation of SRC and attenuates the expression of β-catenin, respectively. Depletion of RNF146 caused hypersensitivity to LPS-induced TNF-α production in vivo. RNF146 thus acts as an inhibitory switch to control osteoclastogenesis and cytokine production and may be a control point underlying the pathogenesis of chronic inflammatory diseases.
RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146 signaling binds to an inhibitory element in the RNF146 promoter to potently repress RNF146 transcription. Finally, we found that dysfunction of the 3BP2 degradation program controlled by RNF146 in mice results in accelerated osteoclastogenesis and hypersensitivity to LPS induction of TNF-α in macrophages.
Our study has unveiled a pathway downstream of RANKL that links bone resorption to inflammatory states, a condition that underlies human diseases, such as rheumatoid arthritis.
Results
RANKL stabilizes 3BP2 and AXIN1 protein levels through suppression of the E3 ubiquitin ligase RNF146. The 3BP2/SRC (14) , Wnt/β-catphorylation, ubiquitylation, and proteasome-dependent degradation (20) . RNF146 targets AXIN for ubiquitylation and destruction and is thus a positive regulator of the Wnt/β-catenin pathway (21) . The molecular basis for repression of the Wnt/β-catenin pathway during osteoclastogenesis is not known.
We show that RANKL simultaneously coordinates activation of SRC through induction of 3BP2 and suppression of β-catenin in addition to its established role in activating NFATc1. We demonstrate that RANKL represses the expression of the E3 ubiquitin ligase RNF146, which results in the stabilization of 3BP2 (15) and AXIN1 (21), leading to activation of SRC and suppression of β-catenin, respectively. We show that activation of NF-κB by RANKL Primary murine macrophages were cultured in the presence or absence of RANKL (50 ng/ml) and a WNT3a-conditioned medium. Whole cell lysates were probed with the indicated antibodies for Western blot analysis. (C) Whole cell lysates from cells in A were probed with the indicated antibodies for Western blot analysis. (D) Primary murine macrophages cultured in the presence or absence of RANKL (50 ng/ml) were treated with 10 μM MG132 for 4 hours prior to collection of cell lysates. 3BP2 immune complexes were probed with an anti-K48 linkage-specific polyubiquitin or anti-3BP2 antibody. (E) qPCR analysis of Rnf146 mRNA expression in primary murine macrophages cultured in the presence or absence of RANKL (50 ng/ml). n = 3. (F) Primary murine macrophages were cultured in the presence or absence of RANKL (50 ng/ml). RNF146 immune complexes were probed with an anti-RNF146 antibody. Whole cell lysates (WCLs) were probed with an anti-GAPDH antibody for Western blot analysis. (G) Primary murine macrophages infected with an empty vector control (mock) or RNF146-expressing retroviral vector were cultured in the presence or absence of RANKL (50 ng/ml). Whole cell lysates were probed with the indicated antibodies for Western blot analysis. (H) TRAP staining of osteoclasts infected with an empty vector control (mock) or RNF146-expressing retroviral vector and cultured in the presence or absence of RANKL for 7 days. Original magnification, ×40. n = 3. P values were determined by ANOVA with Tukey-Kramer's post hoc test (B and G) or unpaired t test (A, C-F, and H). Data are presented as mean ± SEM. *P < 0.05.
Volume 127 Number 4 April 2017 lysine 48 ubiquitylation of 3BP2 without changes in the levels of ADP ribosylation in primary murine macrophages ( Figure 1D and Supplemental Figure 1C ). These results suggest that the attenuated levels of 3BP2 ubiquitylation could be the result of decreased RNF146 expression, activity, or both. Consistent with these results, we found that expression levels of Rnf146 mRNA and protein were reduced in RANKL-treated macrophages ( Figure 1 , E and F). These data suggest that RANKL-induced osteoclastogenesis may in part be mediated by the coordinated stabilization of 3BP2 and suppression of β-catenin, a known inhibitor of osteoclast formation (11) (12) (13) , through the repression of RNF146. To determine whether the stabilization of 3BP2 and AXIN1 by RANKL is achieved specifically through repression of Rnf146 transcription, we sought to rescue this effect by ectopic expression of RNF146. We infected primary murine macrophages with an RNF146-expressing retroviral vector and observed that ectopic expression of RNF146 restored the 3BP2 and AXIN1 expression levels elevated by RANKL to normal levels and impaired osteoclast differentiation ( Figure 1, G and H ). These findings demonstrate that RANKL stabilizes 3BP2 and AXIN1 through suppression of the E3 ubiquitin ligase RNF146, leading to enhanced osteoclastogenesis.
RANKL suppresses RNF146 promoter activity through activation of NF-κB. To elucidate the basis of RANKL transcriptional represenin (11) (12) (13) , and RANKL/RANK (2, 3, 7, 8) pathways are all essential for normal osteoclast differentiation. We conjectured that these 3 pathways could be part of a common integrated signaling pathway during osteoclastogenesis. We first examined the effect of RANKL on levels of AXIN1, a negative regulator of the Wnt/β-catenin pathway, and observed that AXIN1 protein expression was elevated 3-fold by RANKL in primary murine macrophages without enhancement of Axin1 transcripts ( Figure 1A and Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI90527DS1). Additionally, RANKL impaired WNT3a-induced stabilization of β-catenin ( Figure 1B ), suggesting that RANKL-mediated AXIN1 elevation may be functionally coupled to the control of β-catenin. We next examined the effect of RANKL on 3BP2 levels and observed that RANKL also enhanced 3BP2 protein expression 2-fold in primary murine macrophages ( Figure 1C ) without elevation of the Sh3bp2 transcript levels (Supplemental Figure 1B) . These data suggest that both 3BP2 and AXIN1 proteins are likely stabilized through a posttranscriptional mechanism downstream of RANK signaling. In the previous studies, we and others showed that 3BP2 and AXIN1 are negatively regulated through tankyrase-mediated ADP ribosylation, which creates a recognition-binding site for the E3 ubiquitin ligase RNF146 (15, 20, 21) . We observed that RANKL suppressed Figure 2C) , and observed that the P4 mutant construct augmented luciferase activity to levels similar to those of promoter P13 ( Figure 2E ) and that neither P4 mutant nor P13 promoter activity was suppressed by RANKL (Supplemental Figure 2D ). To confirm that NF-κB regulates endogenous Rnf146 transcription, we performed ChIP of the Rnf146 promoter in RAW264.7 cells and observed strong enrichment of an Rnf146-derived amplicon in NF-κB chromatin immunoprecipitates (Figure 2F ). Importantly, we found that recruitment of NF-κB to the Rnf146 promoter was increased 2-fold by RANKL treatment (Figure 2F ). These results are consistent with a model whereby RANKL stabilizes 3BP2 and AXIN1 via NF-κB transcriptional repression of RNF146, leading to enhanced osteoclast differentiation.
RNF146 represses osteoclastogenesis and LPS-mediated TNF-α production in bone marrow-derived osteoclast progenitors.
To test the hypothesis that RANKL-mediated repression of RNF146 coordinates enhanced 3BP2 signaling with the attenuated β-catenin in osteoclasts, we generated Rnf146 conditional knockout mice sion of RNF146, we performed functional analysis of RNF146 promoter cloned into a luciferase reporter construct. We generated 9 constructs derived from a 1-kb RNF146 promoter fragment upstream of the putative transcriptional start site ( Figure 2 , A and B). We observed robust luciferase activity from P1 and P4 promoters, but not from P6 and P7 promoters, in 293T cells, demonstrating that P1 and P4 are active promoter fragments ( Figure 2A and Supplemental Figure 2A ). We next examined the promoter activities in response to RANKL stimulation and observed that RANKL strongly inhibited P4 luciferase activity in a murine macrophage cell line, RAW264.7 ( Figure 2C ). To identify the minimal inhibitory promoter elements in P4 that were responsive to RANKL treatment, we cloned a series of truncated promoter fragments, shown in Figure 2B . Promoter activity derived from all of the smaller fragments was 7 times higher than that of P4 ( Figure 2D ), suggesting the presence of a negative regulatory element between P4 and P13 ( Figure 2 , A and B). To determine the transcription factors that could potentially bind to the negative regulatory region, we analyzed the sequence of P4 that was absent from P13 using MATCH, a transcription factor-binding prediction algorithm (22) , and found a conserved sequence within the RNF146 promoter that corresponded to a potential binding site for NF-κB (Figure Figure  3G ). These findings demonstrate that repression of RNF146 is a critical checkpoint during osteoclast maturation and LPS-induced TNF-α production in bone marrow-derived osteoclast progenitors. (Figure 4 , J and K), indicating enhanced osteoclastogenesis. In contrast, trichrome staining of tibiae showed that osteoid surface per bone surface ( Figure 4L ) and osteoblast number per bone surface ( Figure 4M ) were similar in WT and Rnf146 fl/fl LysM-Cre mice. Moreover, dynamic bone histomorphometric analysis after calcein green labeling revealed that bone formation rate (Figure 4N) , mineral apposition rate ( Figure 4O) , and mineralizing surface ( Figure 4P) Figure 5A ). We queried whether 3BP2 is required to support the emergence of highly active osteoclasts observed in Rnf146 fl/fl LysM-Cre mice and generated Sh3bp2 conditional knockout mice (Sh3bp2 fl/fl LysM-Cre) in which 3BP2 was deleted in osteoclast progenitors (Supplemental Figure 5, A and B) . We observed that deletion of Sh3bp2 in osteoclast progenitors suppressed in vitro osteoclast differentiation and bone resorptive capacity compared with WT cells with a reduction of active SRC levels (Supplemental Figure 5 , C-E), consistent with our previous study (14) . To confirm that deletion of Sh3bp2 could rescue the phonotype observed in Rnf146 fl/fl LysM-Cre mice, we next generated Rnf146 and Sh3bp2 conditional double-knockout mice (Rnf146 fl/fl Sh3bp2 fl/fl LysM-Cre) in which both RNF146 and 3BP2 were deleted in osteoclast progenitors. As shown in Figure 5 , B and C, the highly activated osteoclast phenotype observed in 
Loss of 3BP2 rescued osteopenia observed in Rnf146
fl/fl LysM-Cre mice. We next determined whether the severe osteopenic phenotype observed in Rnf146 fl/fl LysM-Cre mice was dependent on 3BP2. Consistent with our previous study (14) , Sh3bp2 fl/fl LysM-Cre mice showed increased bone mass ( Figure 6A) , with an elevation of trabecular bone volume (Supplemental Figure 6A) , trabecular bone mineral density (Supplemental Figure 6B) , trabecular number (Supplemental Figure 6C) , and trabecular thickness (Supplemental Figure 6D ) compared with WT mice, though trabecular separation was near normal (Supplemental Figure 6E) . Cortical thickness, cortical major diameter, and cortical periosteal perimeter, but not cortical minor diameter and cortical endosteal perimeter, were also increased in Sh3bp2 fl/fl LysM-Cre mice compared with WT mice (Supplemental Figure 6 , F-J). In concert with the data shown in Supplemental Figure 5 , C-E, these results demonstrate that 3BP2 expression in osteoclast progenitors is required for normal osteoclastogenesis and bone resorption to maintain bone mass. We finally confirmed that osteopenia observed in Rnf146 fl/fl LysM-Cre progenitors compared with that in WT cells ( Figure 7D ). We hypothesized that loss of RNF146 accelerated the osteoclast developmental program through stabilization of AXIN1 and subsequent impairment of the Wnt/β-catenin pathway and queried RNF146 leads to decreased macrophage proliferation and increased osteoclastogenesis with attenuated β-catenin expression expands the concept that repression of RNF146 mediates the RANKL-triggered proliferation-to-differentiation switch during osteoclastogenesis. The 3BP2 degradation program controlled by RNF146 is essential for postnatal skeletal remodeling and TNF-α production. RNF146 is recruited to its substrates through its WWE domain, and its E3 ubiquitin ligase activity is triggered by binding to sites of poly(ADPribose) modification. To date, all known RNF146 substrates are ADP ribosylated by tankyrase. 3BP2 is a substrate of both tankyrase and RNF146 (15, 21) . 3BP2 missense mutations, associated with the craniofacial dysmorphia syndrome cherubism, uncouple 3BP2 from tankyrase and block 3BP2 ADP ribosylation and subsequent ubiquitylation by RNF146 (15) . A knockin mouse model expressing one of the cherubism-associated mutations in Sh3bp2 displays osteopenia due to active osteoclastogenesis, and bone marrow-derived macrophages from cherubism mice are more susceptive to LPS-induced TNF-α production (18, 30) . We have shown that Rnf146 fl/fl LysM-Cre mice phenocopy cherubism knockin mice with osteopenia and highly activated osteoclasts and that depletion of 3BP2 in Rnf146 fl/fl LysM-Cre mice restores this phenotype, showing that the 3BP2 degradation program controlled by RNF146 is critical for optimal postnatal skeletal remodeling.
In addition to its role in osteoclastogenesis, we found that RNF146 is a negative regulator of LPS-induced TNF-α production. Hyperresponsive TLR signaling to commensal bacteria may be an early trigger for autoinflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, and periodontitis (31) (32) (33) (34) (35) (36) (37) . These studies suggest 3BP2 and RNF146 as potential human autoinflammatory disease susceptibility genes. Taken together, these data show that RNF146 acts as an inhibitory switch controlling osteoclastogenesis and cytokine production.
RNF146 is a new target for RANKL. In a recent study, J. Luo et al. demonstrated that leucine-rich repeat-containing G proteincoupled receptor 4 (LGR4) is a new receptor for RANKL (38) . They showed that the RANKL/LGR4 signaling pathway inhibits the expression and activity of NFATc1 through activation of Gαq, leading to impairment of osteoclastogenesis, while Lgr4 −/− mice suffer from osteopenia due to activation of the osteoclast developmental program (38) . These results indicate that RANKL provides a dichotomous signal mediated through 2 distinct receptor systems to control osteoclastogenesis. In addition to the developmental effects of RANKL on osteoclastogenesis, lymph node and lymphocyte development, and breast epithelial proliferation (1) (2) (3) (4) (5) (6) , recent studies show a link between RANKL and cancer development. The RANKL/RANK pathway mediates breast cancer driven by progestin, which is commonly used for hormone replacement therapy and contraceptives (39) . Moreover, RANKL is involved in the progression of osteosarcoma caused by mutations in retinoblastoma (RB) and tumor protein p53 (TP53) tumor suppressors (40) , demonstrating that blockade of RANKL could be a therapeutic target for cancer development and progression. Our observation that an interplay between RNF146 and RANKL regulates LysM-Cre progenitors is in part through AXIN1-mediated inhibition of the Wnt/β-catenin pathway.
These findings conclusively demonstrate that repression of RNF146 by RANKL and subsequent stabilization of 3BP2 and AXIN1 are part of a common genetic pathway required for the osteoclast developmental program.
Discussion

RANKL integrates the 3BP2 and β-catenin signaling pathways required for osteoclastogenesis by transcriptional repression of the E3 ubiquitin ligase RNF146.
Osteoclastogenesis is a dynamic process that relies on the activation of distinct signaling pathways that couple to NFATc1, NF-κB, MAPK (24), 3BP2 (14) , SRC, VAV, and SYK and is dependent on the simultaneous repression of β-catenin (11-13). Our findings reveal an unrecognized function of RANKL, coordinating activation of SRC through induction of 3BP2 and repression of β-catenin together with the canonical RANK signaling pathways required for osteoclastogenesis. Specifically, we found a new role of NF-κB as a transcriptional repressor of RNF146 (25) (26) (27) . A reduction of RNF146 expression by NF-κB attenuates ubiquitylation and degradation of its substrates, 3BP2 and AXIN1, leading to activation of SRC kinase and suppression of β-catenin, respectively ( Figure 8 ). We found that ectopic expression of RNF146 in primary murine macrophages was sufficient to disrupt RANKLmediated stabilization of 3BP2 and AXIN1 and blocked osteoclast differentiation, indicating that modulation of RNF146 expression is a critical control point for the osteoclast developmental program. We have demonstrated that Rnf146 LysM-Cre mice showed severe osteopenia due to hyperactivation of osteoclasts as a consequence of stabilization of 3BP2 and impairment of the Wnt/β-catenin pathway. Moreover, deletion of 3BP2 or ectopic expression of active β-catenin rescued the accelerated osteoclastogenic phenotype observed in RNF146-null osteoclast progenitors. These data demonstrate that loss of RNF146-induced osteoclastogenesis is contingent on activation of the 3BP2/SRC pathway and simultaneous repression of the Wnt/β-catenin pathway.
During the process of osteoclast formation, M-CSF promotes monocyte/macrophage proliferation, while RANKL induces osteoclast differentiation (28, 29) . Our observation that loss of Surface Plates according to the manufacturer's protocol. Resorption area was quantified and is shown in the figures. μCT. Femurs from 12-week-old male mice were scanned using μCT (SkyScan 1174, Bruker) at a resolution of 9.1 μm as described previously (14, 15) . Morphometric analysis was performed on a VOI of trabecular bone 1 mm in length beginning 1 mm beneath the first instance of the formation of the mineralized cartilage bridge in the developing metaphysis and on a VOI of cortical bone 0.9 mm in length in the midshaft. 3D images were reconstructed from 0.5-mm regions within the trabecular and cortical VOIs identified above. Trabecular and cortical morphometric parameters were determined according to standard protocols (43) . Trabecular bone mineral density was determined by comparing against a pair of calibration phantoms (SkyScan).
Histomorphometry. In vivo osteoblast parameters were generated from undecalcified tibial sections embedded in methyl methacrylate and stained with Goldner's trichrome. For dynamic histomorphometric analysis, calcein green was injected on days 0 and 7, and mice were sacrificed 3 days after the second calcein injection. In vivo osteoclast parameters were generated from decalcified tibial sections embedded in paraffin and stained for TRAP activity. Images were analyzed using BIOQUANT software (BIOQUANT Image Analysis Corp.).
In vivo LPS challenge. LPS (Sigma-Aldrich) was injected i.p. at a concentration of 1.8 mg/kg. Blood was harvested 4 hours later by cardiac puncture, and TNF-α in the serum was measured by ELISA (eBioscience) as described previously (30) .
Construction and expression of β-catenin (S33Y) and RNF146 retroviral vectors. pMXs-β-catenin (S33Y) was a gift from Shinya Yamanaka (Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan) (44). RNF146 cDNA was purchased from Origene Technologies, and pMXs-RNF146 was constructed as described previously (14) . HEK293T cells were cotransfected with an empty vector control (mock), pMXs-β-catenin (S33Y), or pMXs-RNF146 with pMCV-Ecopac (EcoPak) using a CalPhos Mammalian Transfection Kit (Clontech). The virus was collected 48 hours after transfection, and primary murine macrophages were infected and cultured in the presence of RANKL for osteoclast differentiation assay.
In vivo ubiquitin assay. An in vivo ubiquitin assay was performed as described previously (45, 46) . Briefly, cells cultured in the presence or absence of RANKL (50 ng/ml) were treated with 10 μM MG132 for 4 hours prior to collection of cell lysates. Then cells were lysed in complete cell lysis buffer (2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0) with protease and phosphatase inhibitors, boiled for 10 minutes, sheared with a sonication device, and incubated for 30 minutes at 4°C with dilution buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100). After lysates had been cleared by centrifugation at 14,000 g for 30 minutes at 4°C, immunoprecipitation and Western blotting were performed.
Reagents and antibodies. Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich. Antibodies were obtained from the following sources: anti-pSRC (Y416) (catalog 2101), anti-SRC (catalog 2109), anti-K48 linkage-specific polyubiquitin (catalog 4289), anti-AXIN1 (catalog 2087), anti-β-catenin (catalog 9562), anti-GAPDH (catalog 2118) (Cell Signaling Technology), anti-RNF146 (catalog SAB1408054), anti-Flag M2 (catalog F3165) (SigmaAldrich), anti-actin (catalog sc-47778) (Santa Cruz Biotechnology Inc.), anti-poly(ADP-ribosylation) (anti-PAR) (catalog 4336-APC-050) (Trevigen), and anti-3BP2 (catalog H00006452-M01) (Abnoosteoclastogenesis thus suggests insights into the role of RNF146 for cancer biology though the 3BP2/SRC and Wnt/β-catenin pathways. Further studies will be necessary to investigate RNF146 in multiple lineages and physiologic states.
Methods
Generation of Rnf146 conditional knockout mice. In the targeting vector, the first loxP site was inserted in intron 3, while the second loxP site was placed in the 3′ UTR of exon 4. Essentially, almost all of the coding region of Rnf146 was flanked by 2 loxP sites. The HSVtk-Neo cassette was flanked by 2 FRT sites. Linearized targeting vector DNA was electroporated into C57BL6/J embryonic stem (ES) cells, and G418-resistant ES clones were first screened by nested PCR and then subjected to Southern blot analysis. Targeted ES clones were used for blastocyst injection, and chimeric males were mated with WT C57BL/6J females to obtain F1 mice. The removal of the HSVtk-Neo cassette was achieved by mating the F1 heterozygous mice with FLPe deleter mice on a C57BL/6J background. Rnf146 fl/fl mice were crossed with LysM-Cre mice (The Jackson Laboratory) (41) . Generation of Sh3bp2 conditional knockout mice. Sh3bp2 exons 6 and 7 were targeted (Sh3bp2 tm1a(KOMP)Wtsi ). The allele was initially a knockout due to the presence of a strong splice acceptor-lacZ-Neo cassette inserted before exon 6. Heterozygous F1 mice with this allele were crossed with actin-FLPe mice (The Jackson Laboratory). FLPe deletes the splice acceptor cassette and generates an allele in which exons 6 and 7 are flanked by loxP sites. Fully verified targeted ES cells were obtained from the Wellcome Trust Sanger Institute Mouse Genetics Project (Sanger MGP). The mouse strain was generated at The Centre for Phenogenomics using the ES cell clone EPD0129_3_C05 from the Knockout Mouse Project (KOMP) repository at UCD (Davis, California, USA) (project ID CSD39313). Chimeric mice were generated by diploid aggregation of ES cells, and ICR embryos and heterozygous F1 mice harboring a targeted Sh3bp2 allele were obtained by crossing chimeric males with C57BL/6 female mice. Sh3bp2 fl/fl mice were crossed with LysM-Cre mice.
Genotyping of Rnf146
fl/fl and Sh3bp2 fl/fl mice. Tail DNA was extracted using a Wizard SV Genomic DNA Purification System (Promega), and PCR was performed using GoTaq Green Master Mix (Promega). Floxed alleles were genotyped by PCR using the following primers: Rnf146 (forward primer, 5′-CCAGTCAGACCGATCAGGAACTGAC-3′; reverse primer, 5′-TACTGAACAGCTCTCAACTATCAACACC-3′) and Sh3bp2 (forward primer, 5′-ACAGCTCAGTGTTGGATTCCTGGCTC-3′; reverse primer, 5′-ACCCTGACTGGTCGGTGTTTCAGAAC-3′). Cell cultures. HEK293T cells (ATCC) and RAW264.7 cells (ATCC) were cultured in DMEM (Wisent) supplemented with 10% FBS (Wisent). Bone marrow-derived macrophages were cultured as described previously (15) . All cultures were maintained in a 5% CO 2 environment at 37°C.
Osteoclast differentiation assay. Bone marrow cells were cultured in α-MEM (Gibco, Thermo Fisher Scientific) supplemented with 10% FBS and 2% CMG (conditioned medium supernatant containing recombinant M-CSF, ref. 42) . Osteoclast progenitors were then replated and cultured with recombinant mouse RANKL (10 or 50 ng/ml) for 7 days. TRAP staining was performed using a kit from Sigma-Aldrich according to the manufacturer's protocol. Osteoclast numbers were quantified and are shown in the figures as described previously (14) . Bone resorption pit assay was performed using Corning Osteo Assay
